BTIG analyst Sean Lavin maintained a Buy rating on Endologix Inc (NASDAQ: ELGX) on May 2 and set a price target of $7. The company’s shares closed on Friday at $4.34, close to its 52-week low of $3.75.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.0% and a 63.2% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.
Endologix Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.49 and a one-year low of $3.75. Currently, Endologix Inc has an average volume of 608.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System.
